IL2 and coronary artery disorder: In 2021, the phase I-II LILACS trial showed that subcutaneous administration of escalating doses of recombinant IL-2 in 44 patients with stable CAD or NSTEMI resulted in a dose-dependent increase in circulating Treg levels, without significant adverse events [87].The ongoing phase II double-blind, placebo-controlled IVORY trial is investigating the administration of low-dose IL-2 within 14 days of hospital admission in 60 ACS patients, with hs-CRP levels > 2 mg/L.